{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:21:58Z","timestamp":1783146118994,"version":"3.54.6"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["OJQDSP2022007"],"award-info":[{"award-number":["OJQDSP2022007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021ZD0203400"],"award-info":[{"award-number":["2021ZD0203400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430045"],"award-info":[{"award-number":["82430045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neuropharm.2026.111036","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:29:28Z","timestamp":1779492568000},"page":"111036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The adenosine A2A receptor antagonist KW6002 mitigates aldosterone-induced central serous chorioretinopathy in mice"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-4686","authenticated-orcid":false,"given":"Qiaoli","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3966-4431","authenticated-orcid":false,"given":"Zijun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-hang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-nan","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Fan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111036_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6793-5-10","article-title":"Adenosine infusion increases plasma VEGF levels in humans","volume":"5","author":"Adair","year":"2005","journal-title":"BMC Physiol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/glia.23579","article-title":"Blockade of microglial adenosine A(2A) receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells","volume":"67","author":"Aires","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2026.111036_bib3","first-page":"96","article-title":"Topical nepafenac in treatment of acute central serous chorioretinopathy","volume":"2","author":"Alkin","year":"2013","journal-title":"Med. Hypothesis, Discov. Innovation (MEHDI) Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib4","first-page":"708","article-title":"Measurement of choroidal thickness following caffeine intake in healthy subjects","volume":"41","author":"Altinkaynak","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajo.2011.04.008","article-title":"A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy","volume":"152","author":"Bae","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2147\/OPTH.S202047","article-title":"Treatment of central serous chorioretinopathy with topical NSAIDs","volume":"13","author":"Bahadorani","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000443893","article-title":"Therapeutic opportunities for caffeine and A2A receptor antagonists in retinal diseases","volume":"55","author":"Boia","year":"2016","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.451","article-title":"Treatment with A(2A) receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage","volume":"8","author":"Boia","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2026.111036_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107754","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: review of the pre-clinical and clinical evidence","volume":"187","author":"Bousquet","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107747","article-title":"Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents","volume":"187","author":"Canonica","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib13","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1523\/JNEUROSCI.19-21-09192.1999","article-title":"A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice","volume":"19","author":"Chen","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mam.2017.01.001","article-title":"Adenosine receptors and caffeine in retinopathy of prematurity","volume":"55","author":"Chen","year":"2017","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.neuropharm.2026.111036_bib15","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.biocel.2008.05.016","article-title":"Adenosine-stimulated adrenal steroidogenesis involves the adenosine A2A and A2B receptors and the Janus kinase 2-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase signaling pathway","volume":"40","author":"Chen","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2026.111036_bib16","article-title":"Caffeine protects against retinal inflammation","volume":"12","author":"Conti","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70269-7","article-title":"The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis","volume":"10","author":"de Vries","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.111036_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/TCRM.S138581","article-title":"Neutrophil\/lymphocyte ratio and mean platelet volume in central serous chorioretinopathy","volume":"13","author":"Erol","year":"2017","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.neuropharm.2026.111036_bib20","first-page":"707","article-title":"A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin)","volume":"63","author":"Fasih","year":"2013","journal-title":"J. Pakistan Med. Assoc."},{"key":"10.1016\/j.neuropharm.2026.111036_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102441","article-title":"Strategies for drug delivery into the brain: a review on adenosine receptors modulation for central nervous system diseases therapy","volume":"15","author":"Fernandez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuropharm.2026.111036_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"issue":"Suppl. l","key":"10.1016\/j.neuropharm.2026.111036_bib23","first-page":"1","article-title":"Pathogenesis of disciform detachment of the neuroepithelium","volume":"63","author":"Gass","year":"1967","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib24","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/eye.2010.130","article-title":"Central serous chorioretinopathy: an update on pathogenesis and treatment","volume":"24","author":"Gemenetzi","year":"2010","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.neuropharm.2026.111036_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/path.4870","article-title":"Activating the AKT2-nuclear factor-\u03baB-lipocalin-2 axis elicits an inflammatory response in age-related macular degeneration","volume":"241","author":"Ghosh","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","article-title":"Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure","volume":"18","author":"Gismondi","year":"2009","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.neuropharm.2026.111036_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18502\/jovr.v18i1.12725","article-title":"Adenosine receptors expression in human retina and choroid with age-related macular degeneration","volume":"18","author":"Goebel","year":"2023","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archopht.1994.01090200063023","article-title":"Digital indocyanine green videoangiography of central serous chorioretinopathy","volume":"112","author":"Guyer","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/eye.2016.109","article-title":"Rate of intraoperative complications during cataract surgery following intravitreal injections","volume":"30","author":"Hahn","year":"2016","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.neuropharm.2026.111036_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ophtha.2015.06.040","article-title":"Effect of prior Anti-VEGF injections on the risk of retained lens fragments and endophthalmitis after cataract surgery in the elderly","volume":"123","author":"Hahn","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neuropharm.2026.111036_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ophtha.2010.08.017","article-title":"Fundus autofluorescence and visual acuity in central serous chorioretinopathy","volume":"118","author":"Imamura","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neuropharm.2026.111036_bib32","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1111\/aos.14547","article-title":"Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy","volume":"99","author":"Karska-Basta","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12035-014-8879-2","article-title":"A2A adenosine receptor regulates the human blood-brain barrier permeability","volume":"52","author":"Kim","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in olmsted county, Minnesota, 1980-2002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neuropharm.2026.111036_bib36","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216525","article-title":"HIF2\u03b1 activation and mitochondrial deficit due to iron chelation cause retinal atrophy","volume":"15","author":"Kong","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2026.111036_bib37","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1167\/iovs.18-25018","article-title":"Changes in stromal and luminal areas of the choroid in pachychoroid diseases: insights into the pathophysiology of pachychoroid diseases","volume":"59","author":"Lee","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1167\/iovs.15-18024","article-title":"The effect of A2A receptor antagonist on microglial activation in experimental glaucoma","volume":"57","author":"Liu","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1350-9462(02)00058-7","article-title":"Retinal vascular development and oxygen-induced retinopathy: a role for adenosine","volume":"22","author":"Lutty","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77202-y","article-title":"Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy","volume":"10","author":"Matet","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.111036_bib41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies","volume":"31","author":"McCannel","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.neuropharm.2026.111036_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1755-3768.2010.02064.x","article-title":"Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections","volume":"89","author":"Meyer","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100264","article-title":"Current pharmacological treatment options for central serous chorioretinopathy: a review","volume":"13","author":"Nicol\u00f2","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.neuropharm.2026.111036_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100252","article-title":"International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-Retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI)","author":"Radke","year":"2025","journal-title":"Asia Pac. J. Ophthalmol (Phila)"},{"key":"10.1016\/j.neuropharm.2026.111036_bib47","article-title":"Epigallocatechin gallate suppresses inflammation in human coronary artery endothelial cells by inhibiting NF-\u03baB","volume":"258","author":"Reddy","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10633-022-09872-0","article-title":"ISCEV standard for full-field clinical electroretinography (2022 update)","volume":"144","author":"Robson","year":"2022","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib49","first-page":"Cd011841","article-title":"Interventions for central serous chorioretinopathy: a network meta-analysis","volume":"2015","author":"Salehi","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2026.111036_bib50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/01.hjh.0000170379.08214.5a","article-title":"Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB\/IkappaB system","volume":"23","author":"Sanz-Rosa","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.neuropharm.2026.111036_bib51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/humu.22551","article-title":"Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy","volume":"35","author":"Schubert","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.neuropharm.2026.111036_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/IAE.0b013e3180307271","article-title":"Reducing the risk of endophthalmitis following intravitreal injections","volume":"27","author":"Scott","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.neuropharm.2026.111036_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1200492","article-title":"The role of inflammation in central serous chorioretinopathy: from mechanisms to therapeutic prospects","volume":"15","author":"Shen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib54","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4103\/ijo.IJO_1327_19","article-title":"Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy","volume":"68","author":"Sirakaya","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108438","article-title":"Topically instilled caffeine selectively alters emmetropizing responses in infant rhesus monkeys","volume":"203","author":"Smith","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.737426","article-title":"Caffeine inhibits choroidal neovascularization through mitigation of inflammatory and angiogenesis activities","volume":"9","author":"Sorenson","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib57","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ophtha.2019.04.037","article-title":"Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor","volume":"126","author":"Storey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neuropharm.2026.111036_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib61","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1523\/JNEUROSCI.2506-18.2019","article-title":"Endothelial Adora2a activation promotes blood-brain barrier breakdown and cognitive impairment in mice with diet-induced insulin resistance","volume":"39","author":"Yamamoto","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111036_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10384-020-00740-5","article-title":"Pachychoroid disease: a new perspective on exudative maculopathy","volume":"64","author":"Yanagi","year":"2020","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12802","article-title":"Melatonin prevents experimental central serous chorioretinopathy in rats","volume":"73","author":"Yu","year":"2022","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.neuropharm.2026.111036_bib64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/15569527.2014.912659","article-title":"The effect of caffeine on choroidal thickness in young healthy subjects","volume":"34","author":"Zengin","year":"2015","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.neuropharm.2026.111036_bib65","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2026.111036_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12974-022-02415-z","article-title":"Choroid plexus-selective inactivation of adenosine A(2A) receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis","volume":"19","author":"Zheng","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.111036_bib67","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100414RR","article-title":"Adenosine A(2A) receptor antagonism protects against hyperoxia-induced retinal vascular loss via cellular proliferation","volume":"35","author":"Zhong","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2026.111036_bib68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10020-018-0038-1","article-title":"Adenosine A(2A) receptor antagonists act at the hyperoxic phase to confer protection against retinopathy","volume":"24","author":"Zhou","year":"2018","journal-title":"Mol. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:14:38Z","timestamp":1783145678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":68,"alternative-id":["S0028390826002091"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111036","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adenosine A2A receptor antagonist KW6002 mitigates aldosterone-induced central serous chorioretinopathy in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111036"}}